Understanding the attitudes toward sunless tanning product use: implication of tanning product consumption

Jeong‑Ju Yoo,Hyeon Jeong Cho 한국의류학회 2018 Fashion and Textiles Vol.5 No.1

The goal of this study is to test the antecedents of overall attitudes toward sunless tanning product use. The data collected from 302 US female college students with an average age of 20.11 were included in the analysis. A structural equation modeling was performed to test the hypothesized relationships. The results revealed that body surveillance and social ostracism influenced the individuals’ cutaneous body image dissatisfaction, which also influenced perceived attractiveness and fitness of tanned appearance. Perceived tanning attractiveness and perceived tanning physical fitness positively influences attitudes toward tanning product use. It is evident that seeing one’s own body through the lens of others is at the root of positive attitudes toward sunless tanning products. Positive attitudinal changes toward sunless tanning products can be successfully established emphasizing sunless tanning products as fashion consumption. The findings in this study have important relevance, in that tanning products can be marketed as cosmetic appearance-enhancement products for people to look attractive, toned, and fit.

신고리 지역 기상관측을 통한 계절별 대기안정도 특성분석

송상근,김유근,오인보,정주희,조윤미,우경은,강태훈 부산대학교 환경문제연구소 2003 環境硏究報 Vol.21 No.-

In this study, we analyzed the characteristics of atmospheric stability to investigate local environment change at an atomic power plant in Gori region. The used data was obtained from field observation of major meteorological variables such as wind direction and speed, air temperature, relative humidity, and solar radiation using AWS (Automatic Weather System) in Gori region from February to September in 2003. As a result, when strong northerly winds (more than 4~6 m/s) and weak northwesterly winds (2~3m/s) blow, atmospheric stability was neutral and stable from winter to spring, respectively. Atmospheric stability (neutral) in summer was similar to that in two other seasons (winter and spring), but it was stable for weak southwesterly winds (2~3 m/s). Finally, atmospheric stability was neutral for strong winds (over 4~6 m/s) in fall without respect to wind direction, while that was stable for very weak winds (less than 2 m/s).

국내 상급종합병원과 종합병원 간호사의 정맥주입간호실무지침의 확산정도

은영(Young Eun),구미옥(Mee Ok Gu),조용애(Young Ae Cho),정재심(Jae Shim Jeong),권정순(Jeong Soon Kwon),유정숙(Cheong Suk Yoo5),정영선(Young Sun Jeong),정인숙(In Sook Jung),김경숙(Kyeong Sug Kim),이선희(Seon Heui Lee),서현주(Hyun Ju S 한국근거기반간호학회 2015 근거와 간호 Vol.3 No.1

Purpose: This study was conducted to investigate the extent of diffusion of Intravenous infusion nursing practice guideline among nurses in advanced general hospitals and general hospitals in Korea. Methods: The subjects were 234 nurses who practice the intravenous infusion in 24 advanced general hospitals and general hospitals. Data were collected between October 5 and November 2, 2015 by mail (return rates: 97.5 %). Data were analyzed using descriptive statistics, t-test, and ANOVA with SPSS/ WIN 21. Results: The average guideline diffusion score and levels of diffusion was 3.39±0.58 (level of “use sometimes”). 44 recommendations (46%) were in level of “use always” and 50 recommendations (53%) were in “use sometimes”. Extent of diffusion were significantly different according to present status (F=2.81, p=.040) and education (F=4.35, p=.014). The facilitating factors to use the guideline were education by department of nursing service, convenient composition of guideline and barrier factors were “no time to use the guideline”, “don’t know the guideline” and “there is no guideline at ward”. Conclusion: Extent of diffusion of Intravenous infusion nursing practice guideline among nurses was moderate level. The strategies for promoting the implementation of guideline in clinical practice is needed. Further study of outcome evaluation of guideline implementation will be needed.

HBV : PE-036 ; Comparison of entecavir, telbivudine, lamivudine in preventing hepatitis B reactivation during chemotherapy

( Jeong Ju Yoo ),( Hwi Young Kim ),( Jeong Hoon Lee ),( Eun Ju Cho ),( Min Sun Kwak ),( Su Jong Yu ),( Yoon Jun Kim ),( Jung Hwan Yoon ),( Hyo Suk Lee ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-

Backgrounds: Hepatitis B virus (HBV) reactivation is a wellknown complication during cytotoxic chemotherapy for malignancies. Thus prophylactic antiviral therapy is needed for preventing HBV reactivation in cancer patients with chronic hepatitis B(CHB). However, data are scarce on proper antiviral agents or duration of therapy to date. In this study, we compared the frequency of hepatitis B reactivation between three different antiviral agents; lamivudine, telbivudine and entecavir. Methods: We retrospectively reviewed the medical records of patients with CHB who received chemotherapy under prophylaxis with one of the antiviral agents - lamivudine, telbivudine, entecavir - from March 2010 to December 2011 at Seoul National University Hospital. Patients with primary liver malignancies (hepatocellular carcinoma or cholangiocarcinoma) were excluded. All patients were observed for HBV reactivation & HBV-related hepatitis which was defined as detectable HBV DNA or AST/ALT elevation during and for 6 months after chemotherapy. Result: A total of 53 patients were enrolled in this study. The mean age of patients was 58.8 years old, and 26 (49.1%) were male. 28 Patients(53%) was treated with lamivudine, 18 patients with telbivudine, 7 patients with entecavir, respectively. Among 53 patients, 7 patients developed HBV reactivation and 5 patients developed HBV-related hepatitis. In HBV reactivation group, 6 patients was treated with lamivudine, 1 patients treated with telbivudine. In HBV-related hepatitis group, 4 patients were treated with lamivudine, 1 patients treated with telbivudine. Either reactivation or HBV-related hepatitis was not reported in entecavir group. Compared with lamivudine and telbivudine, entecavir group had lower tendency of reactivation (p = 0.162) or hepatitis (p = 0.403), but it was not statistically significant. Baseline DNA level was higher in HBV reactivation group (median 31094, range 0-200000) compared with nonreactivated group (median 793, range 0-170000000), and the median time of reactivation was 8 months after chemotherapy. Conclusion: Initial HBV DNA titer was higher in reactivation group compared with non-reactivation group. Entecavir group showed decreased tendency of reactivation or hepatitis compared with lamivudine or telbivudine.

Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B

Jeong-Ju Yoo,Su Jong Yu,Bora Lee,Eun Ju Cho,Jeong-Hoon Lee,Sang Gyune Kim,Yoon Jun Kim,Young Seok Kim,Jung-Hwan Yoon 거트앤리버 소화기연관학회협의회 2020 Gut and Liver Vol.14 No.3

Background/Aims: Patients with an intermediate stage of hepatocellular carcinoma (HCC) represent a highly heterogeneous population; therefore, many models have been proposed to predict the survival of these patients. The aim of this study was to evaluate the prognostic performance of a novel subclassification for tumors classified as Barcelona Clinic Liver Cancer (BCLC) stage B using the Model to Estimate Survival in Ambulatory HCC patients (MESIAH). Methods: This analysis was based on 377 patients with HCC treated at Seoul National University Hospital (training cohort) and 189 patients at the Soonchunhyang University Bucheon Hospital (validation cohort). Four subclassification systems were tested: MESIAH; original BCLC B subclassification (B1, B2, B3, and B4); modified model A (B1, B2, and B3+B4); and modified model B (B1, B2+B3, and B4). Results: Median survival progressively decreased from stage B1 through stages B2 to B3 according to the new MESIAH subclassification (p<0.001). Moreover, significantly different survival among contiguous stages was observed. In the multivariable Cox regression, the MESIAH subclassification was an independent predictor of overall survival (p<0.001). In terms of discrimination and calibration, MESIAH performed better than the original BCLC B subclassification, modified model A and modified model B. Conclusions: The MESIAH model would be an effective tool for stratifying heterogeneous BCLC stage B cancer, and the ability of this model to predict survival is better than that of the other previously proposed models.

Acute kidney injury in patients with acute-on-chronic liver failure: clinical significance and management

( Jeong-ju Yoo ),( Moo Yong Park ),( Sang Gyune Kim ) 대한신장학회 2023 Kidney Research and Clinical Practice Vol.42 No.3

Acute-on-chronic-liver failure (ACLF) refers to a phenomenon in which patients with chronic liver disease develop multiple organ failure due to acute exacerbation of underlying liver disease. More than 10 definitions of ACLF are extant around the world, and there is lack of consensus on whether extrahepatic organ failure is a main component or a consequence of ACLF. Asian and European consortiums have their own definitions of ACLF. The Asian Pacific Association for the Study of the Liver ACLF Research Consortium does not consider kidney failure as a diagnostic criterion for ACLF. Meanwhile, the European Association for the Study of the Liver Chronic Liver Failure and the North American Consortium for the Study of End-stage Liver Disease do consider kidney failure as an important factor in diagnosing and assessing the severity of ACLF. When kidney failure occurs in ACLF patients, treatment varies depending on the presence and stage of acute kidney injury (AKI). In general, the diagnosis of AKI in cirrhotic patients is based on the International Club of Ascites criteria: an increase of 0.3 mg/dL or more within 48 hours or a serum creatinine increase of 50% or more within one week. This study underscores the importance of kidney failure or AKI in patients with ACLF by reviewing its pathophysiology, prevention methods, and treatment approaches.

Prognostic Value of Biochemical Response Models for Primary Biliary Cholangitis and the Additional Role of the Neutrophil-to-Lymphocyte Ratio

( Jeong-ju Yoo ),( Eun Ju Cho ),( Bora Lee ),( Sang Gyune Kim ),( Young Seok Kim ),( Yun Bin Lee ),( Jeong-hoon Lee ),( Su Jong Yu ),( Yoon Jun Kim ),( Jung-hwan Yoon ) 대한소화기학회 2018 Gut and Liver Vol.12 No.6

Background/Aims: Recently reported prognostic models for primary biliary cholangitis (PBC) have been shown to be effective in Western populations but have not been wellvalidated in Asian patients. This study aimed to compare the performance of prognostic models in Korean patients and to investigate whether inflammation-based scores can further help in prognosis prediction. Methods: This study included 271 consecutive patients diagnosed with PBC in Korea. The following prognostic models were evaluated: the Barcelona model, the Paris-I/II model, the Rotterdam criteria, the GLOBE score and the UK-PBC score. The neutrophil-to-lymphocyte ratio (NLR) was analyzed with reference to its association with prognosis. Results: For predicting liver transplant or death at the 5-year and 10-year follow-up examinations, the UK-PBC score (areas under the receiver operating characteristic curve [AUCs], 0.88 and 0.82) and GLOBE score (AUCs, 0.85 and 0.83) were significantly more accurate in predicting prognosis than the other scoring systems (all p< 0.05). There was no significant difference between the performance of the UK-PBC and GLOBE scores. In addition to the prognostic models, a high NLR ( >2.46) at baseline was an independent predictor of reduced transplant-free survival in the multivariate analysis (adjusted hazard ratio, 3.74; p<0.01). When the NLR was applied to the prognostic models, it significantly differentiated the prognosis of patients. Conclusions: The UK-PBC and GLOBE scores showed good prognostic performance in Korean patients with PBC. In addition, a high NLR was associated with a poorer prognosis. Including the NLR in prognostic models may further help to stratify patients with PBC. (Gut Liver 2018;12:714-721)

Medium Optimization and Fermentation Conditions for Mass Production of Bacillus subtilis by Statistical Experimental Design

Yoo-Min JEONG,Ju-Hee LEE,Enkhtsetseg SEROD,Hea-Jong CHUNG,Gie-Taek CHUN,Yong-Seob JEONG 한국생물공학회 2009 한국생물공학회 학술대회 Vol.2009 No.4

Free Paper Session : Hepatitis B ; Clinical courses of proteinuria detected in chronic hepatitis B patients (초)

( Jeong Ju Yoo ),( Jung Hwan Yoon ),( Eun Sun Jang ),( Eun Ju Cho ),( Min Sun Kwak ),( Su Jong Yu ),( Jeong Hoon Lee ),( Yoon Jun Kim ),( Hyo Suk Lee ),( Chung Yong Kim ) 대한간학회 2011 Clinical and Molecular Hepatology(대한간학회지) Vol.17 No.3(S)

HBV : PE-036 ; Comparison of entecavir, telbivudine, lamivudine in preventing hepatitis B reactivation during chemotherapy

( Jeong Ju Yoo ),( Hwi Young Kim ),( Jeong Hoon Lee ),( Eun Ju Cho ),( Min Sun Kwak ),( Su Jong Yu ),( Yoon Jun Kim ),( Jung Hwan Yoon ),( Hyo Suk Lee ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1

Backgrounds: Hepatitis B virus (HBV) reactivation is a wellknown complication during cytotoxic chemotherapy for malignancies. Thus prophylactic antiviral therapy is needed for preventing HBV reactivation in cancer patients with chronic hepatitis B(CHB). However, data are scarce on proper antiviral agents or duration of therapy to date. In this study, we compared the frequency of hepatitis B reactivation between three different antiviral agents; lamivudine, telbivudine and entecavir. Methods: We retrospectively reviewed the medical records of patients with CHB who received chemotherapy under prophylaxis with one of the antiviral agents - lamivudine, telbivudine, entecavir - from March 2010 to December 2011 at Seoul National University Hospital. Patients with primary liver malignancies (hepatocellular carcinoma or cholangiocarcinoma) were excluded. All patients were observed for HBV reactivation & HBV-related hepatitis which was defined as detectable HBV DNA or AST/ALT elevation during and for 6 months after chemotherapy. Result: A total of 53 patients were enrolled in this study. The mean age of patients was 58.8 years old, and 26 (49.1%) were male. 28 Patients(53%) was treated with lamivudine, 18 patients with telbivudine, 7 patients with entecavir, respectively. Among 53 patients, 7 patients developed HBV reactivation and 5 patients developed HBV-related hepatitis. In HBV reactivation group, 6 patients was treated with lamivudine, 1 patients treated with telbivudine. In HBV-related hepatitis group, 4 patients were treated with lamivudine, 1 patients treated with telbivudine. Either reactivation or HBV-related hepatitis was not reported in entecavir group. Compared with lamivudine and telbivudine, entecavir group had lower tendency of reactivation (p = 0.162) or hepatitis (p = 0.403), but it was not statistically significant. Baseline DNA level was higher in HBV reactivation group (median 31094, range 0-200000) compared with nonreactivated group (median 793, range 0-170000000), and the median time of reactivation was 8 months after chemotherapy. Conclusion: Initial HBV DNA titer was higher in reactivation group compared with non-reactivation group. Entecavir group showed decreased tendency of reactivation or hepatitis compared with lamivudine or telbivudine.